A groundbreaking study shows how Zepbound, a popular weight loss medication, could become a key treatment for heart failure ...

About Zappy Health: Customers say they were drawn to the online provider by its low prices, its lack of subscription fees and ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

A new study suggests popular weight-loss drugs like Ozempic and Zepbound may be linked to rare eye conditions that could ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The situation is causing the FDA regulatory headaches and, more seriously, posing ...

US rival Eli Lilly last month forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, leading the stock to fall 8%. The shares have since recovered. "We see an ...

Analysts are particularly optimistic about the demand for tirzepatide, the active ingredient in Eli Lilly's flagship products Mounjaro and Zepbound. Eli Lilly's product portfolio is anchored by ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.

Eli Lilly is playing catch-up to Novo ... The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide ...

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.